A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs). We aimed to assess AZA’s effectiveness regarding r...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Arpit, Srivastava, M. V. Padma, Bhatia, Rohit, Goyal, Vinay, Singh, Mamta Bhushan, Vishnu, Venugopalan Y., Prabhakar, Anuj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526455/
https://www.ncbi.nlm.nih.gov/pubmed/37759850
http://dx.doi.org/10.3390/brainsci13091249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526455/
https://www.ncbi.nlm.nih.gov/pubmed/37759850
http://dx.doi.org/10.3390/brainsci13091249

Ejemplares similares